Comparative efficacy of Sorafenib, and Lenvatinib in Hepatocellular Carcinoma: a meta-analysis
![Thumbnail](/xmlui/bitstream/handle/10361/23930/18346083_PHR.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2023-11Publisher
Brac UniversityAuthor
Monayem, Kazi FahimMetadata
Show full item recordAbstract
Hepatocellular carcinoma (HCC) is an important healthcare problem with developing
therapeutic options. This meta-analysis evaluates the effectiveness and safety of lenvatinib and
sorafenib, focusing largely on overall survival, progression-free survival, and adverse events.
Both drugs promote overall and progression-free survival; however, lenvatinib outperforms the
other in the latter regard. There are differences in safety profiles; sorafenib has larger
confidence intervals and more prominent effects. Publication bias is negligible. Due to
demographic considerations, care should be used when applying these results to different
groups of people. This analysis contributes to our understanding of the therapeutic options for
HCC by providing insightful information that researchers and healthcare providers may use
when deciding on an option of treatment.